Leavell Investment Management Inc. decreased its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 3.3% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 15,614 shares of the medical instruments supplier’s stock after selling 540 shares during the period. Leavell Investment Management Inc.’s holdings in Becton Dickinson and were worth $3,342,000 at the end of the most recent quarter.
Several other hedge funds have also modified their holdings of BDX. Beach Investment Management LLC. purchased a new stake in Becton Dickinson and in the second quarter valued at approximately $2,218,000. Sigma Planning Corp boosted its position in Becton Dickinson and by 5.5% in the 2nd quarter. Sigma Planning Corp now owns 7,213 shares of the medical instruments supplier’s stock worth $1,407,000 after purchasing an additional 375 shares in the last quarter. Wedbush Securities Inc. boosted its position in Becton Dickinson and by 64.9% in the 2nd quarter. Wedbush Securities Inc. now owns 2,931 shares of the medical instruments supplier’s stock worth $572,000 after purchasing an additional 1,154 shares in the last quarter. Foster Dykema Cabot & Co. Inc. MA purchased a new stake in Becton Dickinson and in the 2nd quarter worth approximately $4,383,000. Finally, UMB Bank N A MO boosted its position in Becton Dickinson and by 9.6% in the 2nd quarter. UMB Bank N A MO now owns 72,761 shares of the medical instruments supplier’s stock worth $14,196,000 after purchasing an additional 6,352 shares in the last quarter. Institutional investors and hedge funds own 75.53% of the company’s stock.
Shares of Becton Dickinson and Co (NYSE:BDX) traded down $1.86 during mid-day trading on Thursday, hitting $224.56. The stock had a trading volume of 1,275,200 shares, compared to its average volume of 1,656,328. The company has a current ratio of 5.58, a quick ratio of 5.03 and a debt-to-equity ratio of 1.44. The firm has a market cap of $51,730.00, a P/E ratio of 48.29, a price-to-earnings-growth ratio of 1.70 and a beta of 1.07. Becton Dickinson and Co has a twelve month low of $168.86 and a twelve month high of $229.68.
Becton Dickinson and (NYSE:BDX) last announced its earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.37 by $0.03. Becton Dickinson and had a return on equity of 20.56% and a net margin of 8.52%. The business had revenue of $3.17 billion during the quarter, compared to the consensus estimate of $3.14 billion. During the same period in the prior year, the company posted $2.12 EPS. The business’s quarterly revenue was down 2.0% on a year-over-year basis. research analysts forecast that Becton Dickinson and Co will post 10.89 EPS for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, December 29th. Investors of record on Friday, December 8th were paid a $0.75 dividend. This is an increase from Becton Dickinson and’s previous quarterly dividend of $0.73. This represents a $3.00 annualized dividend and a yield of 1.34%. The ex-dividend date was Thursday, December 7th. Becton Dickinson and’s dividend payout ratio is currently 64.52%.
BDX has been the topic of several recent research reports. Royal Bank of Canada restated a “hold” rating and issued a $210.00 price objective on shares of Becton Dickinson and in a research report on Wednesday, October 25th. Zacks Investment Research downgraded Becton Dickinson and from a “hold” rating to a “sell” rating in a research note on Monday, October 9th. Deutsche Bank set a $260.00 target price on Becton Dickinson and and gave the stock a “buy” rating in a research note on Friday, December 29th. Stifel Nicolaus reaffirmed a “buy” rating and set a $245.00 target price on shares of Becton Dickinson and in a research note on Friday, November 3rd. Finally, Morgan Stanley upped their target price on Becton Dickinson and from $205.00 to $245.00 and gave the stock an “equal weight” rating in a research note on Friday, November 3rd. Five analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. Becton Dickinson and has a consensus rating of “Buy” and a consensus target price of $230.20.
COPYRIGHT VIOLATION WARNING: “Becton Dickinson and Co (BDX) Shares Sold by Leavell Investment Management Inc.” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/01/11/becton-dickinson-and-co-bdx-shares-sold-by-leavell-investment-management-inc.html.
About Becton Dickinson and
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.